Chieron Active Ingredients is an API manufacturer based in India. It holds 14 active US drug master files across a filed portfolio of 11 molecules. Its most recent recorded inspection, by US FDA, closed on 15 November 2019 as VAI. Customs aggregates show $4.0M of exports covering 120 molecules to 31 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Spsr Nellore, India | 3006897905 |
| Molecule | Regulators | Docs |
|---|---|---|
| Olmesartan | US FDA | 2 |
| Tetracaine | US FDA | 2 |
| Warfarin | US FDA | 2 |
| Dapagliflozin | US FDA | 1 |
| Lacosamide | US FDA | 1 |
| Levetiracetam | US FDA | 1 |
| Linagliptin | US FDA | 1 |
| Risperidone | US FDA | 1 |
| Rivaroxaban | US FDA | 1 |
| Sitagliptin | US FDA | 1 |
| Vildagliptin | US FDA | 1 |
Also appears on these molecule pages
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $2.5M | 17 |
| 2025 | Not reported | $4.0M | 31 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Chieron Active Ingredients comes back tiered against every other supplier able to file there.
Start for free